Natalie B. Gulrajani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natalie B. Gulrajani has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Courtney Elise. Wimberly
Department of Neurosurgery and Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine
11 shared publications - Daniel Landi
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, USA
11 shared publications - Jeffrey B. Russ
Department of Pediatrics, Division of Neurology, Duke University, Durham, USA
11 shared publications - John K. Wiencke
Department of Neurological Surgery, University of California San Francisco, San Francisco, USA
11 shared publications - Joseph L. Wiemels
Center for Genetic Epidemiology, Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, USA
11 shared publications - Kyle M. Walsh
Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina
11 shared publications
Latest Publications
- Open Access
- 8 December 2025
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (5-6) , 892-903
Evolving Features of RASopathies Among Pregnancies With Abnormal Fetal Fluid Collections
Objective: We aimed to characterize the fetal features across gestation and describe genotype‐phenotype correlations for pregnancies with fetal RASopathies that were more severely affected as they presented with at least one abnormal fluid collection. Method: Retrospective cohort study of pregnancies with a fetal RASopathy and one or more abnormal fluid collections. Ultrasound and clinic databases were searched at six institutions to identify pathogenic or likely pathogenic variants indicating a fetal RASopathy. Phenotypic features were organized by gestational age to evaluate their evolution, and chi‐square and Fisher exact proportions were compared. Results: Forty‐six pregnancies were included. Pleural effusions, skin edema, ascites, and cardiac abnormalities presented across gestation. Cystic hygroma and jugular sacs presented in the first trimester and persisted into the second trimester. Hepatomegaly, polyhydramnios, small or absent stomach, and contractures were more frequent in the second and third trimesters. Contractures were more likely with HRAS variants (63% vs. 24%, p = 0.044) and increased nuchal translucency or cystic hygroma were more common with SOS1 variants (100% vs. 44%, p = 0.049). Conclusion: These data provide insight into genotype‐phenotype correlations and the course of fetal RASopathies that present with at least one abnormal fluid collection. Timing of these phenotypes is important to consider for future research on targeted in utero approaches to management.
- 8 December 2025
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (5-6) , 892-903
Open AccessEvolving Features of RASopathies Among Pregnancies With Abnormal Fetal Fluid Collections
Objective: We aimed to characterize the fetal features across gestation and describe genotype‐phenotype correlations for pregnancies with fetal RASopathies that were more severely affected as they presented with at least one abnormal fluid collection. Method: Retrospective cohort study of pregnancies with a fetal RASopathy and one or more abnormal fluid collections. Ultrasound and clinic databases were searched at six institutions to identify pathogenic or likely pathogenic variants indicating a fetal RASopathy. Phenotypic features were organized by gestational age to evaluate their evolution, and chi‐square and Fisher exact proportions were compared. Results: Forty‐six pregnancies were included. Pleural effusions, skin edema, ascites, and cardiac abnormalities presented across gestation. Cystic hygroma and jugular sacs presented in the first trimester and persisted into the second trimester. Hepatomegaly, polyhydramnios, small or absent stomach, and contractures were more frequent in the second and third trimesters. Contractures were more likely with HRAS variants (63% vs. 24%, p = 0.044) and increased nuchal translucency or cystic hygroma were more common with SOS1 variants (100% vs. 44%, p = 0.049). Conclusion: These data provide insight into genotype‐phenotype correlations and the course of fetal RASopathies that present with at least one abnormal fluid collection. Timing of these phenotypes is important to consider for future research on targeted in utero approaches to management.
- 9 May 2025
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 233 (4) , 333.e1-333.e11
Genetic diseases underlying a spectrum of fetal effusions
- 9 May 2025
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 233 (4) , 333.e1-333.e11
Genetic diseases underlying a spectrum of fetal effusions
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Supplementary File 1 - contains MCC Diagnosis Survey
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Supplementary File 1 - contains MCC Diagnosis Survey
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Data from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Background:The association between childhood cancer risk and maternal prenatal substance use/abuse remains uncertain due to modest sample sizes and heterogeneous study designs.Methods:We surveyed parents of children with cancer regarding maternal gestational use of tobacco, alcohol, and illicit drugs, using a Likert-type scale, and demographic, perinatal, and clinical variables. Multivariable log-Poisson regression assessed differences in frequency of prenatal substance use across fifteen childhood cancer subtypes, adjusting for birthweight, gestational age, and demographic factors.Results:Respondents from 3,145 unique families completed the survey (92% biological mothers). A minority reported gestational use of tobacco products (14%), illicit drugs including marijuana or cocaine (4%), or more than a moderate amount of alcohol (2%). Prenatal illicit drug use was associated with increased prevalence of intracranial embryonal tumors [prevalence ratio (PR) = 1.94; confidence interval [CI], 1.05–3.58], including medulloblastoma (PR = 1.82) and supratentorial primitive neuroectodermal tumors (PNET; PR = 2.66), and was also associated with retinoblastoma (PR = 3.11; CI, 1.20–8.08). Moderate to heavy alcohol consumption was strongly associated with elevated prevalence of non-Hodgkin lymphoma (PR = 5.94; CI, 1.84–19.21). Prenatal smoking was not associated with elevated prevalence of any childhood cancer subtype.Conclusions:We identify novel associations between illicit drug use during pregnancy and increased prevalence of nonglioma central nervous system tumors, including medulloblastoma, supratentorial PNETs, and retinoblastoma. Gestational exposure to alcohol was positively associated with non-Hodgkin lymphoma.Impact:Although alcohol and tobacco use during pregnancy has declined, gestational cannabis use has risen. Investigating its impact on neurodevelopment and brain tumorigenesis is vital, with important implications for childhood cancer research and public health education.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Background:The association between childhood cancer risk and maternal prenatal substance use/abuse remains uncertain due to modest sample sizes and heterogeneous study designs.Methods:We surveyed parents of children with cancer regarding maternal gestational use of tobacco, alcohol, and illicit drugs, using a Likert-type scale, and demographic, perinatal, and clinical variables. Multivariable log-Poisson regression assessed differences in frequency of prenatal substance use across fifteen childhood cancer subtypes, adjusting for birthweight, gestational age, and demographic factors.Results:Respondents from 3,145 unique families completed the survey (92% biological mothers). A minority reported gestational use of tobacco products (14%), illicit drugs including marijuana or cocaine (4%), or more than a moderate amount of alcohol (2%). Prenatal illicit drug use was associated with increased prevalence of intracranial embryonal tumors [prevalence ratio (PR) = 1.94; confidence interval [CI], 1.05–3.58], including medulloblastoma (PR = 1.82) and supratentorial primitive neuroectodermal tumors (PNET; PR = 2.66), and was also associated with retinoblastoma (PR = 3.11; CI, 1.20–8.08). Moderate to heavy alcohol consumption was strongly associated with elevated prevalence of non-Hodgkin lymphoma (PR = 5.94; CI, 1.84–19.21). Prenatal smoking was not associated with elevated prevalence of any childhood cancer subtype.Conclusions:We identify novel associations between illicit drug use during pregnancy and increased prevalence of nonglioma central nervous system tumors, including medulloblastoma, supratentorial PNETs, and retinoblastoma. Gestational exposure to alcohol was positively associated with non-Hodgkin lymphoma.Impact:Although alcohol and tobacco use during pregnancy has declined, gestational cannabis use has risen. Investigating its impact on neurodevelopment and brain tumorigenesis is vital, with important implications for childhood cancer research and public health education.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Univariate associations between prenatal substance use and childhood cancer subtype
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Univariate associations between prenatal substance use and childhood cancer subtype
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Associations between prenatal substance use and childhood cancer subtype in subset of biological mother respondents
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Associations between prenatal substance use and childhood cancer subtype in subset of biological mother respondents
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Supplementary File 1 - contains MCC Diagnosis Survey
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Supplementary File 1 - contains MCC Diagnosis Survey
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Associations between prenatal substance use and childhood cancer subtype in subset of biological mother respondents
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Associations between prenatal substance use and childhood cancer subtype in subset of biological mother respondents
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Data from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Background:The association between childhood cancer risk and maternal prenatal substance use/abuse remains uncertain due to modest sample sizes and heterogeneous study designs.Methods:We surveyed parents of children with cancer regarding maternal gestational use of tobacco, alcohol, and illicit drugs, using a Likert-type scale, and demographic, perinatal, and clinical variables. Multivariable log-Poisson regression assessed differences in frequency of prenatal substance use across fifteen childhood cancer subtypes, adjusting for birthweight, gestational age, and demographic factors.Results:Respondents from 3,145 unique families completed the survey (92% biological mothers). A minority reported gestational use of tobacco products (14%), illicit drugs including marijuana or cocaine (4%), or more than a moderate amount of alcohol (2%). Prenatal illicit drug use was associated with increased prevalence of intracranial embryonal tumors [prevalence ratio (PR) = 1.94; confidence interval [CI], 1.05–3.58], including medulloblastoma (PR = 1.82) and supratentorial primitive neuroectodermal tumors (PNET; PR = 2.66), and was also associated with retinoblastoma (PR = 3.11; CI, 1.20–8.08). Moderate to heavy alcohol consumption was strongly associated with elevated prevalence of non-Hodgkin lymphoma (PR = 5.94; CI, 1.84–19.21). Prenatal smoking was not associated with elevated prevalence of any childhood cancer subtype.Conclusions:We identify novel associations between illicit drug use during pregnancy and increased prevalence of nonglioma central nervous system tumors, including medulloblastoma, supratentorial PNETs, and retinoblastoma. Gestational exposure to alcohol was positively associated with non-Hodgkin lymphoma.Impact:Although alcohol and tobacco use during pregnancy has declined, gestational cannabis use has risen. Investigating its impact on neurodevelopment and brain tumorigenesis is vital, with important implications for childhood cancer research and public health education.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Background:The association between childhood cancer risk and maternal prenatal substance use/abuse remains uncertain due to modest sample sizes and heterogeneous study designs.Methods:We surveyed parents of children with cancer regarding maternal gestational use of tobacco, alcohol, and illicit drugs, using a Likert-type scale, and demographic, perinatal, and clinical variables. Multivariable log-Poisson regression assessed differences in frequency of prenatal substance use across fifteen childhood cancer subtypes, adjusting for birthweight, gestational age, and demographic factors.Results:Respondents from 3,145 unique families completed the survey (92% biological mothers). A minority reported gestational use of tobacco products (14%), illicit drugs including marijuana or cocaine (4%), or more than a moderate amount of alcohol (2%). Prenatal illicit drug use was associated with increased prevalence of intracranial embryonal tumors [prevalence ratio (PR) = 1.94; confidence interval [CI], 1.05–3.58], including medulloblastoma (PR = 1.82) and supratentorial primitive neuroectodermal tumors (PNET; PR = 2.66), and was also associated with retinoblastoma (PR = 3.11; CI, 1.20–8.08). Moderate to heavy alcohol consumption was strongly associated with elevated prevalence of non-Hodgkin lymphoma (PR = 5.94; CI, 1.84–19.21). Prenatal smoking was not associated with elevated prevalence of any childhood cancer subtype.Conclusions:We identify novel associations between illicit drug use during pregnancy and increased prevalence of nonglioma central nervous system tumors, including medulloblastoma, supratentorial PNETs, and retinoblastoma. Gestational exposure to alcohol was positively associated with non-Hodgkin lymphoma.Impact:Although alcohol and tobacco use during pregnancy has declined, gestational cannabis use has risen. Investigating its impact on neurodevelopment and brain tumorigenesis is vital, with important implications for childhood cancer research and public health education.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Univariate associations between prenatal substance use and childhood cancer subtype
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Univariate associations between prenatal substance use and childhood cancer subtype